Recently another company has entered the US marketplace to contend with the reknowned brand Botox, manufactured by Allergan. Botox has reigned supreme in the aesthetic procedures market in the States, with few real rivals. Up to now the primary substitute to Botox in the States has been Dysport, although many medical practitioners have avoided employing this medicine for cosmetic procedures thanks to some evidence indicating that the drug has a tendency to have more local side effects.
Merz, a Frankfurt based company, is the maker of Xeomin, a botulinum toxin product. Xeomin has been widely used in Europe and enjoyed by doctors and patients alike. Lately in July 2011, Merz released an announcement that the FDA had approved Xeomin for use in the US and that the product would be available for sale in the spring of 2012. This news is a bonus for aesthetics consumers!
While in the USA Xeomin is a fairly unknown medication it has got many advantages over the more famous injectable Botox. Botox must be either stored in a freezer or refrigerator before reconstitution and is highly sensitive to heat as well as to agitation. For instance, when adding diluent to Botox prior to use, physicians must be extremely careful to insert the solution slowly, since forceful insertion could ruin the toxin and cause it to be ineffective.
Xeomin,as opposed to Botox, is a much more resilient medication. A significant edge over Botox is that Xeomin can be kept at 70 degrees and so doesn’t need special storage techniques. In addition Xeomin is a lot less sensitive to agitation. This means that on the part of the clinic less botulinum toxin will be damaged due to poor handling.
In contrast to the other alternative to Botox, Xeomin is far more like Botox in terms of its mechanism of action. Xeomin injections usually remain localized, which means potentially less side effects connected with local spread. Another major advantage is that the units used are the same as the units used by Botox, in constrast to Dysport where the units aren’t matching and can often be a little confusing for doctors.
Additionally, if the US market follows Europe, the introduction of Xeomin will tend to drive the cost of Botox injections downwards. Currently the cost of Botox in America tends to be around $9-12 per unit, while the price in the UK tends to be significantly lower at approximately $7-8 per unit.
Thus the recent introduction of Xeomin into the US market will be a boon for both customers as well as doctors.
Botox Course runs the #1 injection course for medical practitioners to instruct them how to inject Botox and start succesful aesthetic day spas. As well as the Injection Course, physicians can learn skin filler injection methodologies and chemical peeling techniques.